Neutralizing activity and 3-month durability of tixagevimab and cilgavimab prophylaxis against Omicron sublineages in transplant recipients
Andrew H. Karaba(Johns Hopkins University), William A. Werbel(Johns Hopkins University), Robin K. Avery(Johns Hopkins University), Tihitina Y. Aytenfisu(Johns Hopkins University), Yolanda Eby(Johns Hopkins University), Jake D. Kim(Johns Hopkins University), Aura T. Abedon(Johns Hopkins University), Trevor S. Johnston(Johns Hopkins University), Alexa Jefferis(Johns Hopkins University), Feben Habtehyimer(Johns Hopkins University), Teresa Po‐Yu Chiang(Johns Hopkins University), Allan B. Massie(Johns Hopkins University), Dorry L. Segev(New York University), Ioannis Sitaras(Johns Hopkins University), Maggie Li(Johns Hopkins University), Casey Hussey(Johns Hopkins University), Rivka Abedon(Johns Hopkins University), Daniel Warren(Johns Hopkins University), Nicole Fortune(Johns Hopkins University), Andrew Pekosz(Johns Hopkins University), Aaron A.R. Tobian(Johns Hopkins University), Jessica E. Ruff(Johns Hopkins University), Letitia Thomas(Johns Hopkins University), Jennifer L. Alejo(Johns Hopkins University), William Clarke(Johns Hopkins University)
Cited by 12
Related Papers
Foot strike patterns and collision forces in habitually barefoot versus shod runners
|Nature|2010|1.4k
Clinical Practice Guidelines From the AABB
|JAMA|2016|1.1k
The Banff 2017 Kidney Meeting Report: Revised diagnostic criteria for chronic active T cell–mediated rejection, antibody-mediated rejection, and prospects for integrative endpoints for next-generation clinical trials
|American Journal of Transplantation|2017|1k
Antibody Response to 2-Dose SARS-CoV-2 mRNA Vaccine Series in Solid Organ Transplant Recipients
|JAMA|2021|1k
Deployment of convalescent plasma for the prevention and treatment of COVID-19
|Journal of Clinical Investigation|2020|863